Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth. | Bristol Myers Squibb has reported phase 3 wins in a ...
Tortugas Neuroscience’s schizophrenia drug from Hansoh Pharma has proven its worth in a phase 2b study, validating the ...
Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led ...
Parkinson’s disease cell therapy-focused Aspen Neuroscience and bispecific biotech Bambusa Therapeutics are the latest drug ...
One year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA ...
As a notorious night owl, it was already very early in the morning of October 5 when Karl Deisseroth, M.D., Ph.D., finally ...
GSK has joined Chai Discovery’s growing roster of Big Pharma clients, signing up to access protein-folding and design models.
Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results